• SPX
  • $5,739.02
  • 0.76 %
  • $43.08
  • DJI
  • $42,041.24
  • 0.21 %
  • $86.99
  • N225
  • $38,937.54
  • -1 %
  • -$395.20
  • FTSE
  • $8,190.61
  • -1.36 %
  • -$113.01
  • IXIC
  • $18,131.51
  • 1.16 %
  • $207.60
Assembly Biosciences, Inc. (ASMB) Stock Price, News & Analysis

Assembly Biosciences, Inc. (ASMB) Stock Price, News & Analysis

Currency in USD Disclaimer

$14.42

-$0.3

(-2.04%)

Day's range
$14.3
Day's range
$14.78
50-day range
$12.3
Day's range
$19.93
  • Country: US
  • ISIN: US0453962070
52 wk range
$7.68
Day's range
$20.04


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -9.61
  • Piotroski Score 4.00
  • Grade Neutral
  • Symbol (ASMB)
  • Company Assembly Biosciences, Inc.
  • Price $14.42
  • Changes Percentage (-2.04%)
  • Change -$0.3
  • Day Low $14.30
  • Day High $14.78
  • Year High $20.04

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $35.50
  • High Stock Price Target $36.00
  • Low Stock Price Target $35.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$10.58
  • Trailing P/E Ratio -1.35
  • Forward P/E Ratio -1.35
  • P/E Growth -1.35
  • Net Income $-61,228,000

Income Statement

Quarterly

Annual

Latest News of ASMB

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.